Surrogate Measures of Outcome in Clinical Trials
نویسندگان
چکیده
منابع مشابه
evaluation of treatment outcome measures in irritable bowel syndrome clinical trials
background: in clinical trials of irritable bowel syndrome (ibs), evaluation of treatment efficacy is still mainly subjective.we compared three outcome measures in reflecting response to treatment in a clinical trial of ibs. â materials and methods: sixty three adult ibs patients participated in a placebo-controlled trial of 10-wk cognitive-behavioral therapy. patients completed the ibs-qualit...
متن کاملStatistical validation of surrogate outcome measures
With the large number of promising new molecules that are currently available for clinical testing, clinical trials need to detect a drug’s benefit (or harm) as quickly as possible. In parallel with the need for speed in clinical development, advances in molecular biology, high throughput technologies and imaging techniques provide investigators with an ever growing number of biomarkers which c...
متن کاملOutcome measures in amyotrophic lateral sclerosis clinical trials.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an average survival of 3-5 years. While therapies for ALS remain limited, basic and translational ALS research has been host to numerous influential discoveries in recent years. These discoveries have led to a large pipeline of potential therapies that await testing in clinical trials. Until recently, ALS clinical trials ha...
متن کاملNovel Outcome Measures for Clinical Trials in Cystic Fibrosis
Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to assess the disease, its progression and response to treatment. As there are limitations to the curr...
متن کاملOutcome Measures in Clinical Trials for Multiple Sclerosis
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess the true efficacy of interventions in clinical trials. In phase III trials in MS, the traditionally used primary clinical outcome measures are the Expanded Disability Status Scale and the relapse rate. Seco...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurosurgery
سال: 2008
ISSN: 0148-396X,1524-4040
DOI: 10.1227/01.neu.0000335793.88007.ce